Afobazole is a selective non-benzodiazepine anxiolytic. Acting on sigma-1 receptors in brain nerve cells, Afobazole stabilizes GABA / benzodiazepine receptors and restores their sensitivity to endogenous inhibitory mediators. Afobazole also increases the bioenergetic potential of nerve cells and protects them from damage (it has a neuroprotective effect). The action of the drug is implemented mainly in the form of a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Afobazole reduces or eliminates feelings of anxiety (preoccupation, misgivings, fears, irritability), tension (timidity, tearfulness, anxiety, inability to relax, insomnia, fear), somatic manifestations of anxiety (muscle, sensory, cardiovascular, respiratory, gastrointestinal intestinal symptoms), autonomic disorders (dry mouth, sweating, dizziness), cognitive disorders (difficulty concentrating, impaired memory). Especially shown is the use of the drug in individuals with predominantly asthenic personality traits in the form of anxious suspiciousness, insecurity, increased vulnerability and emotional lability, a tendency to emotional-stress reactions. The effect of the drug develops on the 5-7th day of treatment. The maximum effect is achieved by the end of 4 weeks of treatment and persists after an average of 1-2 weeks after treatment. Afobazole causes muscle weakness, drowsiness and does not have a negative effect on concentration and memory. With its use, drug dependence is not formed and the “withdrawal" syndrome does not develop.
INDICATIONS FOR USE
Afobazole is used in adults with anxiety conditions:
- Generalized anxiety disorders
- Adaptation disorders in patients with various somatic diseases (bronchial asthma, irritable bowel syndrome, systemic lupus erythematosus, coronary heart disease, hypertension, arrhythmias)
- dermatological, oncological and other diseases
- Sleep disorders associated with anxiety, neurocirculatory dystonia, premenstrual syndrome, alcohol withdrawal syndrome, to alleviate the "withdrawal" syndrome when quitting smoking
INSTRUCTION FOR USE
For oral administration, after food. The optimal single dose is 10 mg; daily allowance - 30 mg, distributed in 3 doses throughout the day. The duration of the course of the drug is 2-4 weeks. If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment up to 3 months. Overdose With a significant overdose and intoxication, the development of a sedative effect and increased drowsiness without manifestations of muscle relaxation is possible. As an emergency, caffeine 20% solution in ampoules of 1.0 ml 2-3 times a day subcutaneously is used. Special instructions The drug does not adversely affect the driving of vehicles and the performance of potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.
Contraindications Individual intolerance to the drug Afobazole. Galactose intolerance, lactase deficiency or glucose-galactose malabsorption. Pregnancy, lactation. Children under 18 years old. Side effects Allergic reactions are possible. Rarely, a headache that usually goes away on its own and does not require discontinuation of the drug. Interaction Afobazole does not interact with ethanol and does not affect the hypnotic effect of thiopental. Enhances the anticonvulsant effect of carbamazepine. It causes an increase in the anxiolytic effect of diazepam.